Startups

Gliknik receives $15M payment from Pfizer after reaching clinical milestone

The University of Maryland BioPark company's candidate drug is being developed to treat a rare neurological disorder.

The University of Maryland BioPark. (Courtesy photo)

Baltimore biopharmaceutical startup Gliknik said human trials began for a candidate drug it’s developing to treat a rare neurological disorder.

With the beginning of the Phase I clinical trial, the University of Maryland BioPark-based company received a $15 million payment from pharmaceutical giant Pfizer. The payment is tied to a licensing deal between the company and Pfizer, which was initially inked in 2013.

Gliknik is developing a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), which the company said is not derived from blood. It’s designed to meet the effectiveness of a blood product called Intravenous Immune Globulin, which is used to treat autoimmune diseases. Previously, the candidate received orphan drug designation from the U.S. Food and Drug Administration in 2015.

“Beginning the Phase I clinical trial is an important milestone in the development of this drug candidate,” said Gliknik CEO David S. Block in a statement. “We are hopeful that Pfizer’s clinical development efforts will lead to more treatment options for patients with CIDP.”

Under the licensing deal, Pfizer could also receive royalties on sales if the products are commercialized.

Companies: Gliknik

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Baltimore is setting a national standard for diversifying its economy

19 tech and entrepreneurship events to check out before the holidays

Tech lab space opening in new 4MLK building, thanks to $2M in public funds

EDA officials are ‘hopeful’ Tech Hubs program will live on under Trump

Technically Media